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Fibronectins isolated from human plasma @FN) and from the conditioned media of normal (N-cFN) and 
tumor (T-cFN) human cells were compared by cathepsin D digestion followed by immunostaining of re- 
leased fragments with the monoclonal antibody 3E3, specific for the cell binding site. Two different staining 
patterns were obtained, one specific for pFN and N-cFN, the second common to fibronectins from the 3 
different kinds of tumors studied. This indicates tructural differences between N-cFN and T-cFN in the 
cell binding region of the fibronectin molecule. 
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1. INTRODUCTION 
Fibronectins (FNs) are high molecular mass 
adhesive glycoproteins present in soluble form in 
plasma and other body fluids and in insoluble 
form in the extracellular matrices and basement 
membranes. FN molecules act as bridges between 
cell and extracellular materials. In fact FN 
molecules contain a cell binding site and binding 
sites for collagen, heparin, ganglioside and fibrin. 
Due to their polyvalency FNs play an important 
role in diverse biological phenomena including cell 
adhesion, establishment and maintenance of nor- 
mal morphology, cell migration, hemostasis and 
thrombosis, wound healing, ability to induce a 
more normal phenotype in transformed cells and 
metastatic processes (reviews on distribution, 
structure and biological functions [l-S]). 
Recently a highly sensitive and specific pro- 
cedure has been developed to compare the domain 
structure of FNs from different sources based on 
cleavage of FN by a proteolytic enzyme, fractiona- 
tion on SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE), followed by immunoblotting 
analysis with domain specific monoclonal an- 
tibodies [9-lo]. 
Using this procedure and a monoclonal antibody 
specific for the cell binding site we compared FNs 
released by cultured normal human fibroblasts and 
by 3 cell lines originating from human tumors. The 
results indicate structural differences in the cell 
binding segment between FNs from normal and 
tumor cells. . 
2. MATERIALS AND METHODS 
2.1. Cell lines 
Cultured normal fibroblast cell lines (GM-5659, 
human skin; GM-5386, fetal human skin, Human 
Genetic Mutant Cell Repository, Camden, NJ) and 
tumor cell lines derived from human fibrosar- 
coma, HT-1080, embryonal rhabdomyosarcoma, 
RD and melanoma, IgR3 were grown in Eagle’s 
minimum essential medium supplemented with 
10% fetal calf serum (Flow Laboratories, Irvine, 
Scotland) which had been depleted of bovine FN 
by passage through a large capacity gelatin- 
Sepharose column. 
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FN was purified from human plasma and from specific for the cell binding site of human FN 
the conditioned media of the various cell lines as in (fig.2). This monoclonal antibody reacts, in all the 
[I 11. Cathepsin D (Sigma, St. Louis, MO) diges- 6 FNs analyzed, with 2 high-molecular-mass 
tion of FN was performed according to [12]. The fragments of 200 and 130 kDa which correspond 
monoclonal antibody 3E3, directed to the cell to domains l-2-3 and 4 (200 kDa) and 3 and 4 
binding site [13,14] was a gift of Dr E. Ruoslahti (130 kDa) (see fig.3) [lo] and a low-molecular- 
(La Jolla Cancer Research Foundation, La Jolla, mass fragment (24 kDa). Furthermore this 
CA). SDS-PAGE was carried out as in [ 151 and im- monoclonal antibody reacts with a 43 kDa frag- 
munoblotting as in [16,17]. ment only present in FNs from tumor cells (fig.2). 
3. RESULTS 
Fig.1 shows the polypeptide patterns on 4-18% 
SDS-PAGE gradients of FNs from human plasma 
and from the tissue culture media of normal and 
tumor-derived human cells digested for different 
times by cathepsin D (see legend to fig.1). 4-18070 
SDS-PAGE gradients identical to those shown in 
fig.1 were blotted onto a nitrocellulose sheet and 
reacted with the monoclonal antibody 3E3 which is 
In a range of digestion times from 15 min to 
24 h we have been unable to observe the 43 kDa 
fragment in FNs from plasma or from 6 different 
normal human fibroblast lines (not shown). in FN 
from tumor cells the 43 kDa fragment appears 
after 1 h of digestion and starts to decrease after 
5-6 h of digestion (not shown). 
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Fig.1. 4-18% SDS-PAGE gradients of FNs from 
different sources digested for 2, 4 and 8 h by cathepsin 
D. FNs (2OOpg) were digested with cathepsin D at an 
enzyme/substrate ratio of 1:300 in 1 ml of 50 mM 
sodium acetate (pH 3.5) containing 1.8 mM CAPS, 
0.5 mM EDTA and 0.2 mM phenylmethylsulfonyl 
fluoride at 37°C. Lanes: (1,7 and 13) human pIFN, (2,8 
and 14) FN from conditioned medium of GM-5659 
normal human fibroblasts, (3,9 and 15) FN from 
conditioned medium of GM-5386 normal human 
embryo fibroblasts, (4,lO and 16) FN from conditioned 
medium of IgR3 human melanoma cells, (5,ll and 17) 
FN from conditioned medium of RD human 
rhabdomyosarcoma cells, (6,12 and 18) FN from 
conditioned medium of HT-1080 human fibrosarcoma 
cells. The values on the right are the molecular masses 
Fig.2. Immunoblot analysis of a 4-18% SDS-PAGE 
gradient identical to that shown in fig.1, using the 
monoclonal antibody 3E3. The values on the right are 
the molecular masses (in kDa) of the standards (S). 
Domain: I 2 3 4 5 6 
(in kDa) of the standards (S). 
Fig.3. Model of the domain structure of a subunit of 
human FN. ED and IIICS represent the 2 regions of 
variability due to alternative splicing of primary 
transcript. The model is mainly based on [20,21,28,29]. 
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4. DISCUSSION 
Domain-specific monoclonal antibodies com- 
bined with well characterized proteolytic fragmen- 
tation provide a highly sensitive and specific pro- 
cedure to compare the structure of FNs from dif- 
ferent sources [9,10,18,19]. Using this procedure 
Sekiguchi et al. [9,10] have been able to observe 
differences between human FNs from plasma and 
from normal or SV40 transformed fibroblasts. Us- 
ing the same procedure and a monoclonal antibody 
directed to the cell binding site here we compared 
human FNs from plasma, normal fibroblasts and 
3 different types of human tumors. The im- 
munoblots of these 6 different FNs clearly show 2 
different kinds of patterns (fig.2): one specific for 
pFN and N-cFN, the second one common to FNs 
from the 3 different kinds of tumors. This suggests 
structural differences between pFN, N-cFN and T- 
cFN in the cell binding region either due to dif- 
ferences in the primary sequence or in post- 
translational processing. 
In fact, the heterogeneity of FN seems to be due 
to multiple FN mRNAs arising from a single gene, 
localized on chromosome 2 [17], by differential 
splicing in at least 2 different regions of the 
primary transcript [20,21] (see fig.3) and by post- 
translational processing (glycosylation, phospho- 
rylation and sulfation) [22-271. Most probably FN 
represents a mixture of a number of structurally 
different molecules whose make-up varies depend- 
ing on the FN sources. 
In any case, structural modification in the cell 
binding region, either due to differential splicing 
of the primary transcript or to post-translational 
modification, may have important biological con- 
sequences which could interfere with FN’s ability 
to interact with its cellular receptor. 
This study clearly needs to be extended to a 
larger number of tumor cell lines before the dif- 
ference observed can be considered a general 
phenomenon of tumor cells. Purification and 
characterization of the 43 kDa fragment are under 
way to determine the exact nature of the modifica- 
tions observed. 
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